PGHLProcter & Gamble Health Ltd.
Procter & Gamble Health Q2 FY27 Results: Standalone Net Profit ₹117 Crore on Total Income of ₹316 Crore
- Earnings
- Pharmaceuticals
Reviewed byRachit TripathiBlacklitt Research
Procter & Gamble Health (NSE: PGHL) reported standalone total income of ₹316.31 crore and net profit of ₹117.12 crore for the quarter ended 30 Sep 2026, it said in a filing on 2 Nov 2026.
Key highlights
Standalone
The company on its own, without its subsidiaries
- Total income: ₹316.31 crore, down 3.9% YoY and 14.0% QoQ
- Net profit and EPS: ₹117.12 crore, up 32.3% YoY; basic EPS ₹67.18, up 25.9% YoY
- Exceptional item: ₹31.80 crore gain on the Worli property sale, reported in the quarter ended 30 Jun 2026
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 316 | 329 | -3.9% | 368 | -14.0% | |
| Revenue from operations | 382 | 325 | +17.7% | 364 | +5.2% |
| Other income | 4 | 4 | -8.5% | 4 | +0.3% |
| 117 | 89 | +32.3% | 67 | +75.2% | |
| Profit before tax | 150 | 119 | +26.1% | 97 | +54.2% |
| Finance costs | 0 | 0 | +8.3% | 0 | -7.1% |
| Depreciation | 6 | 6 | 0.0% | 6 | +1.0% |
| Tax expense | 33 | 30 | +8.1% | 30 | +8.1% |
| Net profit margin | 37.03% | 26.90% | +10.13 pp | 18.19% | +18.84 pp |
| EPS, basic (₹) | 67.18 | 53.34 | +25.9% | 38.77 | +73.3% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than total income. Standalone net profit rose 32.3% YoY to ₹117.12 crore, while total income fell 3.9% to ₹316.31 crore. Profit before tax rose 26.1% to ₹150.05 crore, and revenue from operations rose 17.7% to ₹382.49 crore against ₹324.92 crore a year earlier.
The notes say the company sold its Worli office premises in the quarter ended 30 Jun 2026 for ₹33.34 crore and disclosed a gain of ₹31.80 crore as an exceptional item for that June quarter. The filing places the exceptional item in the June quarter, not this one, so this quarter's profit before tax is not shown with that item in it.
Finance costs were ₹0.13 crore, or 0.0% of total income, and depreciation was ₹6.08 crore, flat on a year earlier. Tax expense of ₹32.93 crore is 21.9% of profit before tax, against 25.6% in the year-earlier quarter. Net profit margin rose to 37.0% from 26.9% a year earlier.
Inference
The Board approved the unaudited results on 2 Nov 2026, and the statutory auditors, Haribhakti & Co. LLP, issued a limited review report with an unmodified conclusion. The company has no subsidiary, associate or joint venture as at 30 Sep 2026, and it reports one segment, Pharmaceuticals.
Dividend paid in the six months to 30 Sep 2026 was ₹74.70 crore, the same as a year earlier. Cash and cash equivalents stood at ₹322.86 crore at 30 Sep 2026, against ₹177.24 crore at 31 Mar 2026. The filing does not give the reason for the Worli sale, any further property sales, or any dividend declared for the current period and its record date.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
